Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: The effective management of heterogeneous breast cancer relies on accurate human epidermal growth factor receptor 2 (HER2) status assessment to guide targeted therapy. Currently, core needle biopsy remains the gold standard for accurately determining HER2 status. However, its high cost and invasive nature render it unsuitable for large-scale screening or for dynamic monitoring of HER2 status during treatment.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
